title: Prior caspofungin exposure in patients with hematological malignancies is a risk factor for subsequent fungemia due to decreased susceptibility in Candida spp.: a case-control study in Paris, France.
abstract: Infections due to caspofungin-resistant Candida isolates in patients exposed to caspofungin therapy are increasing. We report here a nested case-control study which aimed at identifying factors associated with bloodstream infections caused by Candida spp. having reduced susceptibility to caspofungin (CRSC) in adults suffering from hematological malignancies. In univariate and multivariate analyses, infections with CRSC were associated with caspofungin exposure in the previous 30 days (odds ratio [OR] = 5.25; 95% confidence interval [95% CI], 1.68-16.35) and with an age of ≤ 65 years (OR = 3.27; 95% CI, 1.26-8.50).
authors.affiliation: INSERM U 657, Paris, France.
authors.forename: Elodie
authors.initials: E
authors.lastname: Blanchard
authors.forename: Olivier
authors.initials: O
authors.lastname: Lortholary
authors.forename: Karine
authors.initials: K
authors.lastname: Boukris-Sitbon
authors.forename: Marie
authors.initials: M
authors.lastname: Desnos-Ollivier
authors.forename: Françoise
authors.initials: F
authors.lastname: Dromer
authors.forename: Didier
authors.initials: D
authors.lastname: Guillemot
mesh_terms: D000368:Aged; D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects* / Q000472:pathogenicity*; D016022:Case-Control Studies; D000077336:Caspofungin; D025141:Drug Resistance, Fungal; D054714:Echinocandins / Q000627:therapeutic use*; D005260:Female; D005602:France; D016469:Fungemia / Q000188:drug therapy*; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D055666:Lipopeptides; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077336:Caspofungin